Aquestive Therapeutics (AQST) Leaps Forward: Will The Rally Continue?

Photo of author
Written By Nathan Goldstein

In a remarkable display of market performance, Aquestive Therapeutics (AQST) recently saw its shares surge by 16%. 

This significant uptick, characterized by a substantial increase in trading volume, adds to the stock’s impressive 93% gain over the past four weeks. 

Such a noteworthy jump in Aquestive Therapeutics’ share price points toward investor optimism and potential future growth, but can this momentum be sustained?

The Catalyst Behind the Surge

The recent spike in Aquestive Therapeutics’ stock price is largely attributable to the company’s announcement regarding its phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film. 

Credit: DepositPhotos

This novel treatment for severe allergic reactions, including anaphylaxis, has met both its primary and secondary endpoints, marking a significant milestone in its development. 

Further bolstering investor confidence was the positive feedback from the FDA Type C meeting, with Aquestive setting sights on filing a new drug application for Anaphylm by the end of 2024.

Read More: Is American Airlines Stock About to Take Off?

Financial Outlook and Market Position

Despite the anticipation surrounding its clinical advancements, Aquestive Therapeutics is projected to report a quarterly loss of $0.09 per share in its upcoming earnings report, indicating a year-over-year change of -181.8%. 

However, revenues are expected to see a 12% increase from the year-ago quarter, reaching $12.47 million. 

This juxtaposition of a growing revenue stream against a backdrop of net losses highlights the company’s current phase of investment in research and development, a critical stage for many specialty pharmaceutical companies.

The Role of Earnings Estimate Revisions

Historically, trends in earnings estimate revisions have shown a strong correlation with short-term stock price movements. 

For Aquestive Therapeutics, the consensus EPS estimate for the quarter has been adjusted 13.3% higher over the last 30 days. 

This revision reflects growing analyst confidence in the company’s financial health and operational efficiency, potentially paving the way for future price appreciation.

Also Read: Spam Blocking App Makes A Prominent Mark in Digital Safety Landscape

Aquestive’s Market Trajectory

As the company gears up for its next earnings report, stakeholders and potential investors are keenly observing Aquestive’s strategic moves and their market implications. 

The positive momentum in earnings revisions and the breakthrough in its Anaphylm study could hint at underlying strength, meriting close watch in the coming months.

Comparing Industry Peers

Aquestive Therapeutics’ journey is not isolated, as other players in the Zacks Medical – Drugs industry, such as Collegium Pharmaceutical (COLL), also show promising trends. 

Collegium Pharmaceutical recently experienced a 2.8% increase in its last trading session, with a 12% return over the past month. This comparative analysis sheds light on the broader industry dynamics and the competitive landscape facing Aquestive.

The Path Forward for Aquestive Therapeutics

Aquestive Therapeutics stands at a pivotal juncture, buoyed by the successful outcomes of its Anaphylm study and positive market reception. While the projected financial losses underscore the challenges inherent in pharmaceutical development, the company’s revenue growth and the optimistic outlook for Anaphylm suggest a bright future. 

Credit: DepositPhotos

The upcoming months will be crucial in determining whether the recent surge in AQST’s stock can evolve into sustained market strength, making Aquestive a notable stock to watch.

Read Next: Will Qurate Retail Group Bounce Back After Making Key Strategic Moves? 


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.